T-lymphocyte function inhibition

T-lymphocyte function inhibition is a biological process and pharmacological state characterized by the dampening of T-cell mediated immune responses, rather than a specific molecular target or receptor [1], [6]. It involves the suppression of T-cell activation, clonal expansion, and the secretion of effector cytokines such as interleukin-2 and interferon-gamma [2], [4]. This physiological state is a primary therapeutic goal in clinical settings involving organ transplantation, where it prevents graft rejection, and in the management of systemic autoimmune diseases like rheumatoid arthritis and lupus [6], [7]. Conversely, in the context of malignancy, T-lymphocyte function inhibition is a key immune-evasion strategy employed by tumors through the upregulation of inhibitory checkpoint molecules like PD-L1 and CTLA-4 [3], [5]. Because it describes a functional outcome, the term covers a diverse array of molecular targets and drugs, ranging from intracellular enzymes to cell surface receptors [2], [4].

Other names

T-cell suppressionT-lymphocyte immunosuppressionT-cell inhibitionImmunosuppression

T-lymphocyte function inhibition is achieved through various molecular pathways: calcineurin inhibitors (e.g., Cyclosporine, Tacrolimus) block the transcription of interleukin-2 (IL-2); mTOR inhibitors (e.g., Sirolimus) prevent cell cycle progression in response to cytokines; and costimulation modulators (e.g., Abatacept) competitively inhibit the binding of CD80/CD86 to CD28, preventing full T-cell activation [1], [4], [6]. In oncology, tumor cells utilize checkpoint pathways like PD-1/PD-L1 to actively induce this inhibition and evade immune surveillance [3], [5].